The expanding proteome of the molecular chaperone HSP90

Cell Cycle

Volumn 11, Issue 7, 2012, Pages 1301-1308

  Samant, Rahul S ^a   Clarke, Paul A ^a   Workman, Paul ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Cancer; HSP90; HSP90 biomarkers; HSP90 inhibitors; HSP90 proteome

Indexed keywords

BORTEZOMIB; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; PROTEIN KINASE; PROTEOME; TANESPIMYCIN;

CANCER CELL; CELL TYPE; DNA DAMAGE; DOWN REGULATION; ENZYME ACTIVITY; HUMAN; MASS SPECTROMETRY; MULTIPLE MYELOMA; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; UPREGULATION;

EID: 84860352218     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.19722     Document Type: Review

References (49)

1. Neckers L, Workman P. Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res 2012; 18:64-76; PMID:22215907.
2. Taipale M, Jarosz DF, Lindquist S. HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol 2010; 11:515-28; http://dx.doi.org/10.1038/nrm2918; PMID:20531426.
3. Sharma K, Vabulas RM, Macek B, Pinkert S, Cox J, Mann M, et al. Quantitative proteomics reveals that Hsp90 inhibition preferentially targets kinases and the DNA damage response. Mol Cell Proteomics 2011; http://dx.doi.org/10.1074/mcp.M111.014654; In press; PMID:22167270.
4. Jhaveri K, Taldone T, Modi S, Chiosis G. Advances in the clinical development of heat-shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta 2011; In press; PMID:22062686.
5. Travers J, Sharp S, Workman P. HSP90 inhibition: two-pronged exploitation of cancer dependencies. Drug Discov Today 2011; http://dx.doi.org/10.1016/j. drudis.2011.12.021, In press; PMID:22245656.
6. da Silva VC, Ramos CH. The network interaction of the human cytosolic 90 kDa heat-shock protein Hsp90: A target for cancer therapeutics. J Proteomics 2012; In press; PMID:22236519; http://dx.doi.org/10.1016/j.jprot.2011.12.028.
7. Hartson SD, Matts RL. Approaches for defining the Hsp90-dependent proteome. Biochim Biophys Acta 2011; PMID:21906632; http://dx.doi.ord/10.1016/j. bbamcr.2011.08.013.
8. Kimura Y, Yahara I, Lindquist S. Role of the protein chaperone YDJ1 in establishing Hsp90-mediated signal transduction pathways. Science 1995; 268:1362-5; http://dx.doi.org/10.1126/science.7761857; PMID:7761857.
9. Nathan DF, Vos MH, Lindquist S. Identification of SSF1, CNS1 and HCH1 as multicopy suppressors of a Saccharomyces cerevisiae Hsp90 loss-of-function mutation. Proc Natl Acad Sci USA 1999; 96:1409-14; http://dx.doi.org/10.1073/ pnas.96.4.1409; PMID:9990037.
10. Zhao R, Davey M, Hsu YC, Kaplanek P, Tong A, Parsons AB, et al. Navigating the chaperone network: an integrative map of physical and genetic interactions mediated by the hsp90 chaperone. Cell 2005; 120:715-27; http://dx.doi.org/10.1016/j.cell.2004.12.024; PMID:15766533.
11. Millson SH, Truman AW, King V, Prodromou C, Pearl LH, Piper PW. A two-hybrid screen of the yeast proteome for Hsp90 interactors uncovers a novel Hsp90 chaperone requirement in the activity of a stress-activated mitogen-activated protein kinase, Slt2p (Mpk1p). Eukaryot Cell 2005; 4:849-60; http://dx.doi.org/10.1128/EC.4.5.849-60.2005; PMID:15879519.
12. Zhao R, Houry WA. Molecular interaction network of the Hsp90 chaperone system. Adv Exp Med Biol 2007; 594:27-36; http://dx.doi.org/10.1007/978-0-387- 39975-1-3; PMID:17205672.
13. McClellan AJ, Xia Y, Deutschbauer AM, Davis RW, Gerstein M, Frydman J. Diverse cellular functions of the Hsp90 molecular chaperone uncovered using systems approaches. Cell 2007; 131:121-35; http://dx.doi.org/10.1016/j.cell. 2007.07.036; PMID:17923092.
14. Echeverría PC, Forafonov F, Pandey DP, Mühlebach G, Picard D. Detection of changes in gene regulatory patterns, elicited by perturbations of the Hsp90 molecular chaperone complex, by visualizing multiple experiments with an animation. BioData Min 2011; 4:15; http://dx.doi.org/10.1186/1756-0381-4-15; PMID:21672238.
15. Falsone SF, Gesslbauer B, Tirk F, Piccinini AM, Kungl AJ. A proteomic snapshot of the human heat-shock protein 90 interactome. FEBS Lett 2005; 579:6350-4; PMID:16263121.
16. Te J, Jia L, Rogers J, Miller A, Hartson SD. Novel subunits of the mammalian Hsp90 signal transduction chaperone. J Proteome Res 2007; 6:1963-73; http://dx.doi.org/10.1021/pr060595i; PMID:17348703.
17. Gong Y, Kakihara Y, Krogan N, Greenblatt J, Emili A, Zhang Z, et al. An atlas of chaperone-protein interactions in Saccharomyces cerevisiae: implications to protein folding pathways in the cell. Mol Syst Biol 2009; 5:275; http://dx.doi.org/10.1038/msb.2009.26; PMID:19536198.
18. Tsaytler PA, Krijgsveld J, Goerdayal SS, Rüdiger S, Egmond MR. Novel Hsp90 partners discovered using complementary proteomic approaches. Cell Stress Chaperones 2009; 14:629-38; http://dx.doi.org/10.1007/s12192-009-0115-z; PMID:19396626.
19. Gano JJ, Simon JA. A proteomic investigation of ligand-dependent HSP90 complexes reveals CHORDC1 as a novel ADP-dependent HSP90-interacting protein. Mol Cell Proteomics 2010; 9:255-70; http://dx.doi.org/10.1074/mcp.M900261- MCP200; PMID:19875381.
20. Moulick K, Ahn JH, Zong H, Rodina A, Cerchietti L, Gomes DaGama EM, et al. Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat Chem Biol 2011; 7:818-26; http://dx.doi.org/10.1038/nchembio.670; PMID:21946277.
21. Clarke PA, Hostein I, Banerji U, Stefano FD, Maloney A, Walton M, et al. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene 2000; 19:4125-33; PMID:10962573; http://dx.doi.org/10.1038/sj.onc.1203753.
22. Banerji U, O'Donnell A, Scurr M, Pacey S, Stapleton S, Asad Y, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005; 23:4152-61; PMID:15961763.
23. Maloney A, Clarke PA, Workman P. Genes and proteins governing the cellular sensitivity to HSP90 inhibitors: a mechanistic perspective. Curr Cancer Drug Targets 2003; 3:331-41; PMID:14529385; http://dx.doi.org/10.2174/ 1568009033481822.
24. Powers MV, Clarke PA, Workman P. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell 2008; 14:250-62; PMID:18772114; http://dx.doi.org/10.1016/j.ccr.2008.08.002.
25. Maloney A, Clarke PA, Naaby-Hansen S, Stein R, Koopman JO, Akpan A, et al. Gene and protein expression profiling of human ovarian cancer cells treated with the heat-shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res 2007; 67:3239-53; PMID:17409432.
26. Schumacher JA, Crockett DK, Elenitoba-Johnson KS, Lim MS. Proteome-wide changes induced by the Hsp90 inhibitor, geldanamycin in anaplastic large cell lymphoma cells. Proteomics 2007; 7:2603-16; http://dx.doi.org/10.1002/pmic. 200700108; PMID:17610208.
27. Song D, Chaerkady R, Tan AC, García-García E, Nalli A, Suárez-Gauthier A, et al. Antitumor activity and molecular effects of the novel heatshock protein 90 inhibitor, IPI-504, in pancreatic cancer. Mol Cancer Ther 2008; 7:3275-84; http://dx.doi.org/10.1158/1535-7163.MCT-08-0508; PMID:18852131.
28. Yao JQ, Liu QH, Chen X, Yang Q, Xu ZY, Hu F, et al. Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin inhibits the proliferation of ARPE-19 cells. J Biomed Sci 2010; 17:30; http://dx.doi. org/10.1186/1423-0127-17-30; PMID:20416086.
29. Dezwaan DC, Freeman BC. HSP90: the Rosetta stone for cellular protein dynamics? Cell Cycle 2008; 7:1006-12; http://dx.doi.org/10.4161/cc.7.8.5723; PMID:18414022.
30. Falsone SF, Gesslbauer B, Rek A, Kungl AJ. A proteomic approach towards the Hsp90-dependent ubiquitinylated proteome. Proteomics 2007; 7:2375-83; http://dx.doi.org/10.1002/pmic.200600996; PMID:17623298.
31. Xu W, Marcu M, Yuan X, Mimnaugh E, Patterson C, Neckers L. Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu. Proc Natl Acad Sci USA 2002; 99:12847- 52; http://dx.doi.org/10. 1073/pnas.202365899; PMID:12239347.
32. da Rocha Dias S, Friedlos F, Light Y, Springer C, Workman P, Marais R. Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res 2005; 65:10686-91; PMID:16322212.
33. Grbovic OM, Basso AD, Sawai A, Ye Q, Friedlander P, Solit D, et al. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc Natl Acad Sci USA 2006; 103:57-62; http://dx.doi.org/10. 1073/pnas.0609973103; PMID:16371460.
34. Neznanov N, Komarov AP, Neznanova L, Stanhope-Baker P, Gudkov AV. Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib. Oncotarget 2011; 2:209-21; PMID:21444945.
35. Molineaux SM. Molecular pathways: targeting proteasomal protein degradation in cancer. Clin Cancer Res 2012; 18:15-20; http://dx.doi.org/10. 1158/1078-0432.CCR-11-0853; PMID:22019514.
36. Richter K, Buchner J. Hsp90: chaperoning signal transduction. J Cell Physiol 2001; 188:281-90; http://dx.doi.org/10.1002/jcp.1131; PMID:11473354.
37. Camphausen K, Tofilon PJ. Inhibition of Hsp90: a multitarget approach to radiosensitization. Clin Cancer Res 2007; 13:4326-30; PMID:17671112.
38. Page TJ, Sikder D, Yang L, Pluta L, Wolfinger RD, Kodadek T, et al. Genome-wide analysis of human HSF1 signaling reveals a transcriptional program linked to cellular adaptation and survival. Mol Biosyst 2006; 2:627-39; PMID:17216044.
39. Pacey S, Wilson RH, Walton M, Eatock MM, Hardcastle A, Zetterlund A, et al. A phase I study of the heat-shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clin Cancer Res 2011; 17:1561-70; PMID:21278242.
40. Workman P, Collins I. Probing the probes: fitness factors for small molecule tools. Chem Biol 2010; 17:561-77; http://dx.doi.org/10.1016/j.chembiol. 2010.05.013; PMID:20609406.
41. Bell AW, Deutsch EW, Au CE, Kearney RE, Beavis R, Sechi S, et al.; HUPO Test Sample Working Group. A HUPO test sample study reveals common problems in mass spectrometry-based proteomics. Nat Methods 2009; 6:423-30; http://dx.doi.org/10.1038/nmeth.1333; PMID:19448641.
42. Williams AJ, Ekins S. The long term cost of inferior database quality. Drug Discov Today 2012; http://www.drugdiscoverytoday.com/view/22579/the-long- term-cost-of-inferior-database-quality/
43. Sreedhar AS, Kalmár E, Csermely P, Shen YF. Hsp90 isoforms: functions, expression and clinical importance. FEBS Lett 2004; 562:11-5; http://dx.doi.org/10.1016/S0014-5793(04)00229-7; PMID:15069952.
44. Eletto D, Dersh D, Argon Y. GRP94 in ER quality control and stress responses. Semin Cell Dev Biol 2010; 21:479-85; http://dx.doi.org/10.1016/j. semcdb.2010.03.004; PMID:20223290.
45. Costantino E, Maddalena F, Calise S, Piscazzi A, Tirino V, Fersini A, et al. TRAP1, a novel mitochondrial chaperone responsible for multi-drug resistance and protection from apoptotis in human colorectal carcinoma cells. Cancer Lett 2009; 279:39-46; http://dx.doi.org/10.1016/j.canlet.2009.01.018; PMID:19217207.
46. Landriscina M, Amoroso MR, Piscazzi A, Esposito F. Heat-shock proteins, cell survival and drug resistance: the mitochondrial chaperone TRAP1, a potential novel target for ovarian cancer therapy. Gynecol Oncol 2010; 117:177-82; http://dx.doi.org/10.1016/j.ygyno.2009.10.078; PMID:19942270.
47. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003; 425:407-10; http://dx.doi.org/10.1038/nature01913; PMID:14508491.
48. Yap TA, Workman P. Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics. Annu Rev Pharmacol Toxicol 2012; 52:549-73; http://dx.doi.org/10.1146/annurev-pharmtox- 010611-134532; PMID:22235862.
49. Santagata S, Hu R, Lin NU, Mendillo ML, Collins LC, Hankinson SE, et al. High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer. Proc Natl Acad Sci USA 2011; 108:18378-83; http://dx.doi.org/10.1073/pnas.1115031108; PMID:22042860.